Yesterday
Lean profits, leaner CEO: Inside the Novo Nordisk miracle
The global chief executive of weight loss drug giant Novo Nordisk, Mike Doustdar, lost 25 kilos – but he did it the old-fashioned way.
This Month
Priceline Pharmacy franchisee sale narrows to final four bidders
There are 91 Infinity group pharmacies on offer, with the portfolio valued between $400 million and $500 million.
Infinity Pharmacy directors claim Wesfarmers blocked sale to rival
The Priceline Pharmacy franchise operator was put into administration by Wesfarmers in December after years of financial difficulty.
Eli Lilly confirms oral GLP-1 weight-loss drug being evaluated by TGA
The expected launch of a second oral GLP-1 in the United States has sparked major interest in Australia.
February
‘Tons of money’: How China supplies untested peptides to the West
The success of weight-loss drugs has driven demand for injectable compounds that claim to improve everything from sleep to skin.
‘I’m very measured’: Sigma CEO’s global ambition for Chemist Warehouse
Vikesh Ramsunder says Chemist Warehouse’s international operations could one day “potentially” exceed the huge Australian store network.
Telix chairwoman quits after brutal year, shares sink
The radiopharmaceutical giant says that Tiffany Olson is leaving for personal reasons, with Caledonia’s Mark Nelson stepping in.
January
Wesfarmers denies Priceline pharmacy closures after receivership move
Wesfarmers took to social media to state that 56 Priceline pharmacies affected by the receivership were not at risk of closing.
Chemist Warehouse, PE in early preps for Wesfarmers’ Infinity sale
Chemist Warehouse and Genesis Capital are far from the only players of their ilk expected to show up as Infinity’s network hits the auction block as expected.
Wesfarmers attacks Priceline franchisee’s debt-fuelled expansion spree
In emails to other store owners, the conglomerate said a deal to save Infinity Pharmacy Group failed because of a lack of trust and failure to pay suppliers.
Wesfarmers abandoned Priceline franchise rescue deal at the last hour
Project Coral was meant to be the new beginning for the largest Priceline franchisee operator. Now, the group is facing a firesale in receivership.
Infinity Pharmacy debacle a $100m-plus stocking stuffer for Wesfarmers
Creditors – including major banks, private credit players and Wesfarmers itself – have been left with three head scratchers.
December 2025
How Ozempic is changing Christmas lunch
From roast turtle and giant cabbages to prawns and pavlova, Australian festive menus have evolved. Weight loss drugs may prompt another adjustment.
Wesfarmers puts more than 50 Priceline pharmacies into receivership
KPMG was appointed receiver of the 54 stores, which are run by Infinity Pharmacy Group and are mostly in Queensland.
Ozempic for pets is coming (yes, really)
GLP-1 drugs for pets could be the next frontier for the blockbuster weight loss and diabetes drugs – and a pilot study is under way in the US on obese cats.
Dennis Bastas’ rise from aspiring car designer to $5b pharma king
The son of Greek immigrants signed a mega-deal this year for his pharmaceutical and beauty empire that propelled him to the upper echelons of the Rich List.
November 2025
The pharmacist from Fitzroy who amassed a $7b fortune with Chemist Warehouse
The pharmacists who’ve been made rich by following Chemist Warehouse’s Mario Verrocchi call him The Godfather. He’s told them to get back to work.
CSL rout hits Australia’s biggest blue-chip investors
Some of Australia’s biggest fund managers have been among the most exposed to the sharp decline in CSL’s shares.
Chalmers kills $672m Mayne takeover on national interest grounds
The drug manufacturer’s shares plunged 23 per cent on the treasurer’s announcement before being placed in a trading halt. Shareholders are furious.
CSL plans $2.3b US manufacturing plant as Trump tariffs loom
The global biotech is promising to create American jobs but has not said where its new plasma therapy manufacturing site will be located.
